Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation
Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation
复制标题
DOI：
10.1111/j.1365-2036.2008.03853.x
复制
发表时间：
2009-01-01
影响因子：
7.6
通讯作者：
Whorwell, P. J.
中科院分区：
文献类型：
--
作者：
Agrawal, A.;Houghton, L. A.;Whorwell, P. J.
背景 腹部肿胀感和周长实际增加是肠易激综合征 (IBS) 的麻烦特征，这在便秘患者中更为常见，尤其是那些便秘患者。目的 确定含有乳双歧杆菌 DN-173 010 的发酵乳制品是否可以减少与胃肠道运输加速和便秘 IBS 症状改善相关的膨胀。方法 单中心、随机、双盲、对照、平行团体研究，其中患者服用测试产品或对照产品 4 周。对 34 名意向治疗患者群体评估了扩张、口腔盲肠和结肠传输以及 IBS 症状。结果与对照产品相比，受试产品导致最大扩张百分比变化显着降低 [中位差 -39%，95% CI (-78, -5)；中位差 -39%，95% CI (-78，-5)； P = 0.02] 并且白天平均膨胀呈减少趋势 [-1.52 cm (-3.33, 0.39)； P = 0.096]。口盲肠加速[-1.2 h (-2.3,0); P = 0.049] 以及结肠 [-12.2 h (-22.8, -1.6)； P = 0.026]观察到转运和总体症状严重程度[-0.5（-1.0，-0.05）； P = 0.032] 也有所改善。结论 这种益生菌改善了客观测量的腹围和胃肠道运输，并减少了症状。这些数据支持这样的概念：加速转运是治疗腹胀的有效策略。
Background A sensation of abdominal swelling (bloating) and actual increase in girth (distension) are troublesome features of irritable bowel syndrome (IBS), which is more common in patients with constipation, especially those with delayed transit.Aim To establish whether a fermented dairy product containing Bifidobacterium lactis DN-173 010 reduces distension in association with acceleration of gastrointestinal transit and improvement of symptoms in IBS with constipation.Methods A single centre, randomized, double-blind, controlled, parallel group study in which patients consumed the test product or control product for 4 weeks. Distension, orocaecal and colonic transit and IBS symptoms were assessed on an intention-to-treat population of 34 patients.Results Compared with control product, the test product resulted in a significant reduction in the percentage change in maximal distension [median difference -39%, 95% CI (-78, -5); P = 0.02] and a trend towards reduced mean distension during the day [-1.52 cm (-3.33, 0.39); P = 0.096]. An acceleration of orocaecal [-1.2 h (-2.3,0); P = 0.049] as well as colonic [-12.2 h (-22.8, -1.6); P = 0.026] transit was observed and overall symptom severity [-0.5 (-1.0, -0.05); P = 0.032] also improved.Conclusions This probiotic resulted in improvements in objectively measured abdominal girth and gastrointestinal transit, as well as reduced symptomatology. These data support the concept that accelerating transit is a useful strategy for treating distension.